ArticleScientific reports2019
Mathematical modeling for bioprocess optimization of a protein drug, uricase, production by Aspergillus welwitschiae strain 1-4.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Sustainable gold nanoparticles using Jania rubens, targeted therapeutic potential in prostate cancer and mechanistic insights via GO/KEGG pathway analysis.Scientific reports · 2026Article
- Purification, biochemical characterization and structural analysis of uricase produced from a new strain of Streptomyces.Biotechnology letters · 2026Article
- Innovative mycosynthesis of chitosan nanoparticles via bionanofactory Penicillium crustosum: optimization, characterization, and application against building-deteriorating fungus, Trichosporon asahii.Biotechnology for biofuels and bioproducts · 2026Article
- Biofabrication, statistical optimization, and characterization of collagen nanoparticles synthesized via Streptomyces cell-free system for cancer therapy.Scientific reports · 2025Article
- Diversity of Culturable Fungi in Two-Phase Olive Mill Waste, a Preliminary Evaluation of Their Enzymatic Potential, and Two NewJournal of fungi (Basel, Switzerland) · 2025Article
- Statistical Optimization of Process Parameters and Purification of Uricase Using IsolateIndian journal of microbiology · 2025Article
- Biofabrication of zinc oxide nanoparticles using Moringa oleifera, characterization and statistical optimization for their application in crystal violet adsorption.Scientific reports · 2025Article
- Article
- Artificial intelligence-based optimization for extracellular L-glutaminase free L-asparaginase production by Streptomyces violaceoruber under solid state fermentation conditions.Scientific reports · 2024Article
- Assessment of the Biocontrol Efficacy of Silver Nanoparticles Synthesized byLife (Basel, Switzerland) · 2024Article
- Streptomyces griseorubens as a microbial cell factory for extracellular uricase production and bioprocess optimization using statistical approach.Microbial cell factories · 2024Article
- Investigation of impact of siderophore and process variables on production of iron enriched Saccharomyces boulardii by Plackett-Burman design.Scientific reports · 2024Article
- A sustainable green-approach for biofabrication of chitosan nanoparticles, optimization, characterization, its antifungal activity against phytopathogenic Fusarium culmorum and antitumor activity.Scientific reports · 2024Article
- Bionanofactory for green synthesis of collagen nanoparticles, characterization, optimization, in-vitro and in-vivo anticancer activities.Scientific reports · 2024Article
- Artificial neural network approach for prediction of AuNPs biosynthesis by Streptomyces flavolimosus, characterization, antitumor potency in-vitro and in-vivo against Ehrlich ascites carcinoma.Scientific reports · 2023Article
- Green fabrication of chitosan nanoparticles using Lavendula angustifolia, optimization, characterization and in‑vitro antibiofilm activity.Scientific reports · 2023Article
- Artificial intelligence-based optimization for chitosan nanoparticles biosynthesis, characterization and in‑vitro assessment of its anti-biofilm potentiality.Scientific reports · 2023Article
- Green synthesis of chitosan nanoparticles, optimization, characterization and antibacterial efficacy against multi drug resistant biofilm-forming Acinetobacter baumannii.Scientific reports · 2022Article
- High Cell Density Culture of DairyFood and bioprocess technology · 2022Review
- Statistical modeling of methylene blue degradation by yeast-bacteria consortium; optimization via agro-industrial waste, immobilization and application in real effluents.Microbial cell factories · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbial uricase is effective protein drug used to treat hyperuricemia and its complications, including chronic gout, also in prophylaxis and treatment of tumor lysis and organ transplants hyperuricemia. Uricase is commonly used as diagnostic reagent in clinical analysis for quantification of uric acid in blood and other biological fluids. Also, it can be used as an additive in formulations of hair coloring agents. A newly isolated strain, Aspergillus sp. 1-4, was able to produce extracellular uricase on a medium containing uric acid as inducer. Phylogenetic analysis based on ITS region sequence analysis and phenotypic characteristics showed that Aspergillus sp. strain 1-4 is closely related to Aspergillus welwitschiae and its nucleotide sequence was deposited in the GenBank database and assigned sequence accession number MG323529. Statistical screening using Plackett-Burman design with 20 runs was applied to screen fifteen factors for their significance on uricase production by Aspergillus welwitschiae. Results of statistical analysis indicated that incubation time has the most significant positive effect on uricase production followed by yeast extract and inoculum size with the highest effect values of 13.48, 5.26 and 4.75; respectively. The interaction effects and optimal levels of these factors were evaluated using central composite design. The maximum uricase production was achieved at incubation time (5 days), yeast extract (2 g/L) and inoculum size (4 mL/50 mL medium) are the optimum levels for maximum uricase production (60.03 U/mL). After optimization, uricase production increased by 3.02-folds as compared with that obtained from the unoptimized medium (19.87 U/mL).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.